• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott, ADA partner on therapeutic nutrition program for people with diabetes

June 26, 2023 By Sean Whooley

Abbott FreeStyle Libre 3 Sensor and mobile app
The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott]
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes.

The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity.

Abbott develops a family of CGMs, the latest being the FreeStyle Libre 3. The company said that, over time, data from CGMs helps people with diabetes learn patterns and create a nutritional plan. That plan can help provide steady glucose levels and the potential for improved clinical outcomes, like lower A1C.

“What people with diabetes eat is a critical part of managing their diabetes,” said Charles “Chuck” Henderson, CEO of the ADA. “Personalized nutrition using CGMs has the potential to revolutionize diabetes management by providing individuals with more data and tools to manage their glucose levels, improve their quality of life, and reduce the risk of diabetes-related complications. The ADA is grateful to Abbott for its continued support of our mission to improve the lives of people impacted by diabetes. ”

The plan for the Abbott – ADA collaboration

Through this partnership, Abbott plans to provide the ADA with a $2.65 million grant over the next three years. It builds upon more than 20 years of cooperation between Abbott and the ADA.

With the grant, ADA can engage with healthcare professionals and opinion leaders to evaluate clinical evidence for CGMs with personalized, therapeutic nutrition.

ADA also plans to launch two pilot programs targeting adults with type 2 diabetes to better understand the role of CGM in personalized therapeutic nutrition. These programs leverage CGM data to understand how they help people with diabetes achieve their objectives. That includes modifications to nutritional intake and dietary habits.

Additionally, ADA intends to host roundtable discussions in collaboration with healthcare experts to review and evaluate existing clinical evidence. The discussions aim to investigate the role of therapeutic nutrition using CGM data and the potential to inform nutrition recommendations.

“Abbott’s FreeStyle Libre technology can be a critical tool for all people living with diabetes, not only those on insulin,” said Robert B. Ford, chair and CEO, Abbott. “We look forward to working with the American Diabetes Association to gather further evidence to show how the technology we designed to be affordable and accessible can provide personalized insights t0 help people make informed decisions about their food and activity.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2023, American Diabetes Association

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS